ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
A synbiotic nanoemulsion modulates metabolic dysfunction and organ functioning in high-fat diet-induced obese mice.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
High-fat diet (HFD)-induced obesity is associated with metabolic disturbance and structural changes in the intestine, liver, kidney, and adipose tissue. This study evaluated the effects of a co-formulated nanoemulsion containing silk fibroin (a proposed prebiotic) and Lactobacillus rhamnosus (a probiotic), referred to here as a synbiotic nanoemulsion, in HFD-induced obese mice. A synbiotic nanoemulsion was prepared using a high-energy method and characterized by UV-visible spectroscopy and FTIR analysis. Forty-eight male mice were randomly divided into eight groups (n = 6) and fed different diet for 16 weeks. Body weight was recorded weekly, following biochemical, histological, and histomorphometric analysis. Compared with the normal diet group (31.82 ± 1.18 g), HFD-fed mice showed a significant increase in body weight (48.7 ± 0.07 g) and severe dyslipidemia, evidenced by elevated total cholesterol (222-276.5 mg/dL), triglycerides (195-289.5 mg/dL), and low-density lipoprotein (104.8-140 mg/dL), with reduced high-density lipoprotein levels (9-23 mg/dL). Synbiotic supplementation significantly reduced blood urea nitrogen (8-10 mg/dL), serum creatinine (0.55-1.0 mg/dL), alanine aminotransferase (28-39 U/L), and aspartate aminotransferase (129-141 U/L). Furthermore, systemic inflammation was also reduced reflected by lowered TNF-α, IL-6, and IL-1β, alongside increased IL-10 levels as compared to HFD group. Histological and histomorphometric analysis showed improved organ architecture in the synbiotic-treated group, with several measurements close to those of the normal diet group. In this HFD mouse model, the fibroin-L. rhamnosus nanoemulsion was associated with lower body weight, improved lipid profile, liver, kidney, and inflammatory markers, and improved tissue morphology. These findings support further study of the formulation. The design does not allow conclusions about synergy, nanoemulsion-specific delivery effects or mechanisms.
Indexed as
Identifiers
42955296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.